论文部分内容阅读
目的:观察依那普利联合卡维地洛治疗风湿性心脏病心力衰竭患者的临床疗效。方法:选取2015年1月-2016年8月我院收治的风湿性心脏病心力衰竭患者64例,随机编号并分为两组,对照组和研究组各32例。两组患者入院后均根据病情实施常规对症治疗,对照组在常规治疗基础上使用依那普利进行治疗,观察组在对照组基础上加用卡维地洛进行治疗。两组均连续治疗6个月。观察两组患者临床治疗效果及药物不良反应发生情况。结果:研究组总有效率93.75%明显高于对照组71.88%,差异具有统计学意义(P<0.05),研究组不良反应总发生率9.38%明显低于对照组34.38%,差异具有统计学意义(P<0.05)。结论:依那普利联合卡维地洛治疗风湿性心脏病心力衰竭,能显著提高患者临床疗效,降低不良反应发生情况,安全有效。
Objective: To observe the clinical efficacy of enalapril combined with carvedilol in the treatment of patients with rheumatic heart disease and heart failure. Methods: Sixty-four patients with rheumatic heart disease and heart failure admitted to our hospital from January 2015 to August 2016 were randomly assigned to two groups, 32 in each of the control group and the study group. Two groups of patients admitted to the hospital after the implementation of conventional symptomatic treatment, the control group on the basis of conventional treatment with enalapril treatment, the observation group on the basis of the control group with carvedilol for treatment. Two groups were treated for 6 months. The clinical efficacy and adverse drug reactions of the two groups were observed. Results: The total effective rate was 93.75% in the study group and 71.88% in the control group, the difference was statistically significant (P <0.05). The total incidence of adverse reactions in the study group was 9.38%, significantly lower than that in the control group (34.38%), the difference was statistically significant (P <0.05). Conclusion: Enalapril combined with carvedilol in the treatment of heart failure of rheumatic heart disease can significantly improve the clinical efficacy of patients, reduce the incidence of adverse reactions, safe and effective.